NIH R01 · 2025
Atrioventricular Block Elimination by Rozanolixizumab Treatment
Abstract Selectively targeting IgG recycling at the maternal-fetal interface to reduce pathogenic IgG by inhibition of the fetal neonatal Fc gamma receptor (FcRn) and acceleration of IgG destruction, carries the potential to eradicate autoantibody mediated diseases affirming the prediction “no antibody, no disease.” The nearly invariant finding of high titer autoantibodies reactive with SSA/Ro52kD and 60kD ribonucleoproteins in pregnancies complicated by cardiac neonatal lupus (cardiac-NL), strongly implicates these autoantibodies as required for the development of disease. Maternal IgG accessibility to the fetal circulation is mediated by binding to syncytiotrophoblast expressed FcRn.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.